The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Product Name	Package Size	NDC	Lot	-	Manufacturer Initial Ship Date
			9J36A	8/31/2022	6/15/2020
			9J36B	8/31/2022	5/27/2020
			9J39A	8/31/2022	11/26/2019
			9J39B	8/31/2022	1/3/2020
			9J39C	8/31/2022	12/20/2019
			9J39D	8/31/2022	12/20/2019
			9J39E	8/31/2022	1/7/2020
			9J42B	8/31/2022	1/28/2020
			9J42C	8/31/2022	1/30/2020
			9K62A	9/30/2022	3/16/2020
			9K62B	9/30/2022	7/17/2020
Lidocaine Hydrochloride Jelly USP, 2%	30ml Tube	17478-711- 31	9K62C	9/30/2022	7/17/2020
			9M04A	11/30/2022	3/31/2020
			9M04B	11/30/2022	3/31/2020
			9JS8A	8/31/2022	12/13/2019
Sodium Chloride Ophthalmic Ointment USP, 5%	3.5g Tube	17478-622- 35	9JS8B	8/31/2022	12/18/2019

Akorn is recalling this product because of the identification of turbidity during sterility testing for a product manufactured on Fill Line #2. Akorn's expansion of the investigation has indicated that while additional products/lots were manufactured on the same line during the investigated timeframe, the assessment of sterility results for the batches listed above showed passing sterility results. Akorn's review of the environmental data associated with these hatches showed no recoveries and no significant shifts or negative trends observed that would indicate systemic microbial contamination. Nonetheless, as a precautionary matter, Akorn is initiating a recall for all lots manufactured on Fill Line #2 during the investigated tlmeframe and within expiry. **This recall is to the retail level**.